Liquidia Corporation Common Stock (LQDA)
Stock · NASDAQ · Health Care
$34.33as of 10/16/2026
Price chart
Active signals
LQDA Signal Track Record
How signals performed across all stocks →What LQDA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | +3.9% | 55% | September 18, 2026 |
| Bollinger Band Breakout | 28 | +7.5% | 61% | September 24, 2026 |
| Bollinger Band Breakdown | 14 | +8.3% | 57% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +5.3% | 50% | June 20, 2025 |
| Any 20-session window (baseline) | +4.4% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also p…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 216
- Website
- www.liquidia.com/
Fundamentals
- 1-day range
- $32.2$35.8
- Market cap
- $7.95B
- P/E (trailing)
- 22.46
- P/E (forward)
- 15.90
- EPS (trailing)
- $1.39
- Dividend yield
- —
- Beta
- 0.50
- Avg. volume
- 2.96M
How Liquidia Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Liquidia Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- LQDALiquidia Corporation Common Stock$34.35▼ 1.24%Market cap $7.95BP/E 22.46$21.94$93.61
- ALKSAlkermes plc Ordinary Shares$41.22▲ 2.79%Market cap $8.11BP/E 99.15$27$55.67
- RYTMRhythm Pharmaceuticals Inc. Common Stock$86.17▼ 2.05%Market cap $7.72BP/E —$74.5$122.2
- TGTXTG Therapeutics Inc. Common Stock$53.97▼ 3.62%Market cap $7.59BP/E 19.42$26.76$59.3
- COGTCogent Biosciences Inc. Common Stock$29.52▲ 0.03%Market cap $7.14BP/E —$13.78$43.73
- IONSIonis Pharmaceuticals Inc. Common Stock$42.94▼ 2.67%Market cap $9.06BP/E —$42.08$86.74
- SYRESpyre Therapeutics Inc. Common Stock$79.9▼ 0.25%Market cap $9.12BP/E —$21.01$110.18
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LQDA Liquidia Corporation Common Stock | $7.95B | 22.46 | $34.35 | ▼ 1.24% | $21.94$93.61 |
| ALKS Alkermes plc Ordinary Shares | $8.11B | 99.15 | $41.22 | ▲ 2.79% | $27$55.67 |
| RYTM Rhythm Pharmaceuticals Inc. Common Stock | $7.72B | — | $86.17 | ▼ 2.05% | $74.5$122.2 |
| TGTX TG Therapeutics Inc. Common Stock | $7.59B | 19.42 | $53.97 | ▼ 3.62% | $26.76$59.3 |
| COGT Cogent Biosciences Inc. Common Stock | $7.14B | — | $29.52 | ▲ 0.03% | $13.78$43.73 |
| IONS Ionis Pharmaceuticals Inc. Common Stock | $9.06B | — | $42.94 | ▼ 2.67% | $42.08$86.74 |
| SYRE Spyre Therapeutics Inc. Common Stock | $9.12B | — | $79.9 | ▼ 0.25% | $21.01$110.18 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Liquidia Settles Bitter Fight With United Therapeuticsbenzinga · 10/14/2026
- Liquidia (NASDAQ:LQDA): An Affordable Growth Case with Discounted Forward ValuationChartMill · 10/9/2026
- Stephen M Bloch Implements A Sell Strategy: Offloads $6.39M In Liquidia StockBenzinga · 10/8/2026
- Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA AccessYahoo · 10/7/2026
- Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face DowngradesYahoo · 10/2/2026
- Wells Fargo Downgrades Liquidia to Equal-Weight, Lowers Price Target to $30Benzinga · 10/2/2026
- Liquidia Shares Tank On Patent Court Loss, Rivals May Just Be Getting StartedSeekingAlpha · 10/2/2026
- HC Wainwright & Co. Maintains Buy on Liquidia, Lowers Price Target to $58Benzinga · 10/2/2026
- United Therapeutics Just Sent Liquidia Stock Lower After Patent BattleYahoo · 10/1/2026
Insider Activity
Insider Actions →- Stephen M. Bloch · October 5, 2026 · Sale235.5K @ $27.13
- Raman Singh · September 14, 2026 · Option Exercise8.5K @ $9.31
- Raman Singh · September 14, 2026 · Sale8.5K @ $66.16
- Raman Singh · September 11, 2026 · Option Exercise8.5K @ $9.31
- Raman Singh · September 11, 2026 · Option Exercise556 @ $8.63
- Raman Singh · September 11, 2026 · Sale9.0K @ $68.62
- Sarah Krepp · September 1, 2026 · Sale274 @ $67.76
- Jason Adair · August 21, 2026 · Option Exercise238 @ $14.2
- Jason Adair · August 21, 2026 · Option Exercise10.8K @ $14.2
- Jason Adair · August 21, 2026 · Option Exercise11.8K @ $9.31
- Jason Adair · August 21, 2026 · Option Exercise9.0K @ $9.31
- Jason Adair · August 21, 2026 · Sale41.8K @ $69.09
- Jason Adair · August 21, 2026 · Sale31.8K @ $69.09
- Katherine Rielly-Gauvin · August 20, 2026 · Option Exercise6.7K @ $2.59
- Katherine Rielly-Gauvin · August 20, 2026 · Option Exercise11.7K @ $2.51
Institutional Ownership
March 31, 2026
- Total shares held
- 66.53M
- Total value held
- $2.45B
- Institutional holders
- 243
- Unknown8.66M
- Unknown8.12M
- Unknown5.49M
- Unknown3.55M
- Unknown2.93M
- Unknown2.54M
- Unknown2.29M
- Unknown1.93M
- Unknown1.92M
- Unknown1.88M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.